Mersana Therapeutics Announces Second Quarter 2018 Financial Results and Provides Business Updates
(WorldNews Health)

Response to the FDA Partial Clinical Hold Submitted This Week Strong Balance Sheet with a cash position of $97M to close Q2 CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today reported financial results and a business update for the second quarter ended June 30, 2018. `Our top priority is to resolve the partial clinical hold placed on our novel drug candidate XMT-1522 for HER2 expressing cancers, and to continue advancing XMT-1536 for solid tumors expressing...